Sanofi Pasteur: The Dengue Vaccine Dilemma Harvard Case Solution & Analysis

In 2012, Sanofi Pasteur was competing to develop a vaccine against dengue, a mosquito-borne condition, and was investigating this product in a Phase IIb trial conducted with school kids in Thailand. But while the nominee vaccine matched a balanced immune response that was good and the high safety expectations,it had a proof of effectiveness of a mere 30%, far below the 70% mark the company had targeted.

Guillaume Leroy, vice president of the Dengue Company at Sanofi Pasteur, reflected on the way and the Phase IIb trial surprising outcome ahead. He had to decide whether to go ahead with the vaccine trials and generation, and if so, needed to create a strategic plan on how to price and deliver the vaccine for an instant roll out.

Sanofi Pasteur The Dengue Vaccine Dilemma case study solution

PUBLICATION DATE: April 28, 2014 PRODUCT #: 514074-PDF-ENG

This is just an excerpt. This case is aboutĀ GLOBAL BUSINESS

Sanofi Pasteur: The Dengue Vaccine Dilemma Case Solution Other Similar Case Solutions like

Sanofi Pasteur: The Dengue Vaccine Dilemma

Share This